ERVW-1 and breast neoplasm: Treating breast cancer cell lines and human breast tumor xenografts with ERV-K specific antibodies resulted in decreased tumor growth and apoptosis supporting ERV-K env is a tumor antigen which can be targeted for therapy (18).